Global Eliquis Market Size By Type (2.5 mg, 5 mg), By Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)), By Region, And Segment Forecasts, 2023 to 2032

The Global Eliquis Market was valued at USD 18.2 billion in 2023 and is projected to surpass USD 30.6 billion by 2031, growing at a CAGR of 6.7% during the forecast period from 2023 to 2031. The market growth is primarily driven by the increasing prevalence of atrial fibrillation (AFib), deep vein thrombosis (DVT), and pulmonary embolism (PE), alongside the rising aging population globally. Eliquis (apixaban), a novel oral anticoagulant (NOAC), is widely prescribed due to its efficacy in reducing the risk of stroke and systemic embolism in patients with nonvalvular AFib. Its favorable safety profile and fewer dietary restrictions compared to warfarin continue to fuel its widespread adoption.

Drivers:

1. Rising Incidence of Cardiovascular Disorders:

The growing prevalence of thromboembolic disorders such as AFib, DVT, and PE globally is a major driver. Eliquis is increasingly being adopted as a preferred therapy due to its superior safety and efficacy.

2. Aging Global Population:

With a significant rise in the elderly population, the number of patients at risk for blood clots and stroke is rising, boosting demand for anticoagulants like Eliquis.

3. Shift Towards NOACs:

Compared to traditional vitamin K antagonists, NOACs like Eliquis offer ease of use, no need for routine INR monitoring, and reduced bleeding risk, accelerating their market share.

Restraints:

1. Patent Expiry and Generic Competition:

The anticipated patent expiration of Eliquis in various countries towards the end of the forecast period is expected to introduce generic competitors, potentially impacting market revenue.

2. High Cost of Therapy:

Despite its benefits, the relatively high cost of Eliquis can be a barrier in price-sensitive regions and among uninsured populations.

Opportunity:

1. Expansion in Emerging Markets:

As awareness of AFib and other thromboembolic conditions increases in Asia-Pacific, Latin America, and Africa, Eliquis holds immense growth potential, especially with improved healthcare infrastructure and access.

2. Potential in Post-Surgical Applications:

Increasing use of Eliquis for thromboprophylaxis in orthopedic and general surgeries presents a lucrative opportunity for market expansion.

Market by System Type Insights:

While Eliquis itself is a singular pharmaceutical product, the market can be segmented based on the formulation and dosage types. The oral tablet segment dominates due to its ease of administration and patient compliance. Among strengths, 5mg tablets hold the largest share, commonly prescribed for long-term stroke prevention in AFib patients.

Market by End-use Insights:

In terms of end use, the hospital pharmacy segment accounted for the largest market share in 2023, due to physician prescriptions for inpatient care and discharge regimens. However, the retail pharmacy segment is expected to see robust growth, supported by increased outpatient prescriptions and greater accessibility through mail-order pharmacies.

Market by Regional Insights:

North America dominated the Eliquis market in 2023, driven by high diagnosis rates, advanced healthcare systems, and favorable reimbursement policies. Europe follows closely due to wide clinical adoption. However, Asia-Pacific is expected to exhibit the highest CAGR during the forecast period, supported by rising disease awareness, healthcare modernization, and growing aging populations in countries like China and Japan.

Competitive Scenario:

The global Eliquis market is primarily driven by Bristol-Myers Squibb and Pfizer Inc., who jointly market the drug. The competitive landscape is characterized by strong patent protection, aggressive marketing strategies, and ongoing clinical research for expanded indications. With patent cliffs approaching, major pharmaceutical players are preparing for generic entry, reshaping future competition.

Scope of Work – Global Eliquis Market

Report Metric Details

Market Size (2023) USD 18.2 Billion

Projected Market Size (2031) USD 30.6 Billion

CAGR (2023–2031) 6.7%

Market Segments By Formulation Type, End-use, Region

Growth Drivers Aging population, Rising AFib prevalence, Preference for NOACs

Opportunities Expansion in emerging markets, Post-surgical applications

Key Market Developments:

2023: Bristol-Myers Squibb and Pfizer announced a collaboration with AI-based platforms to optimize patient selection for Eliquis therapy, enhancing personalized medicine initiatives.

2024: Eliquis expanded its label in the EU for broader use in postoperative thromboembolism prevention.

2025: Generic manufacturers filed applications in key markets for post-patent entry, preparing for the anticipated expiration of exclusivity.

FAQs:

1) What is the current market size of the Global Eliquis Market?

The market was valued at USD 18.2 billion in 2023.

2) What is the major growth driver of the Global Eliquis Market?

The increasing prevalence of AFib and related cardiovascular conditions is the key driver.

3) Which is the largest region during the forecast period in the Global Eliquis Market?

North America is the largest region, driven by high adoption and healthcare access.

4) Which segment accounted for the largest market share in Global Eliquis Market?

The hospital pharmacy segment held the largest share in 2023.

5) Who are the key market players in the Global Eliquis Market?

Key players include Bristol-Myers Squibb and Pfizer Inc.

Let me know if you'd like the content in a specific file format or for another market!